COMP <GO>
PNTG vs USPH // EV/EBITDA & P/E VALUATION
The Pennant Group Inc. (NASDAQ) VS. U.S. Physical Therapy Inc. (NYSE) • 15-METRIC TALLY: PNTG 3
— USPH 9
▲ EV/EBITDA & P/E VALUATION LEADER: USPH
LAST: $42.48 (+0.76%) • MKT CAP: $1.48B
valuation
23.9x
LAST: $86.57 (+1.47%) • MKT CAP: $1.29B
valuation
16.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PNTG VS. USPH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PNTG | USPH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 19.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.00% | 11.50% | -0.50 | USPH | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 23.9x | 16.3x | +7.60 | USPH | /valuation <GO> |
| Free Cash Flow Yield | 2.44% | 5.81% | -3.37 | USPH | /fcf-yield <GO> |
| Operating Margin | 5.50% | 11.10% | -5.60 | USPH | /operating-margins <GO> |
| Net Profit Margin | 3.10% | 5.10% | -2.00 | USPH | /net-margins <GO> |
| Revenue Growth (YoY) | 36.30% | 16.30% | +20.00 | PNTG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.12% | -2.12 | USPH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.81 | 2.94 | -0.13 | USPH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | USPH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.6 | 52.3 | +1.36 | PNTG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 42.2x | 27.4x | +14.80 | USPH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.48B | $1.29B | $191.9M | PNTG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PNTG REV | USPH REV | PNTG GROSS % | USPH GROSS % | PNTG FCF | USPH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $947.7M | $781.0M | — | 19.2% | $36.3M | $75.1M |
| FY 2024 | $695.2M | $671.3M | — | 18.5% | $30.3M | $74.9M |
| FY 2023 | $544.9M | $604.8M | — | — | $33.1M | $82.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PNTG // BETA —
USPH // BETA —